Has participated in:
-
Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma
-
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
-
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood
-
Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling